肝细胞肝癌放射治疗研究进展  

Advances in radiotherapy for hepatocellular carcinoma

作　　者：姆尼热·阿卜力米提 谭遥[1] 伊斯刊达尔·阿布力米提[1] Munire·Abulimiti;TAN Yao;Yisikandaer·Abulimiti(Department of Thoracic and Abdominal Radiotherapy,Affiliated Tumor Hospital of Xinjiang Medical University,Xinjiang Urumqi 830011,China)

机构地区：[1]新疆医科大学附属肿瘤医院胸腹放疗科,新疆乌鲁木齐830011

出　　处：《现代肿瘤医学》2021年第10期1817-1821,共5页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81760499)。

摘　　要：肝细胞肝癌(hepatocellular carcinoma,HCC)是世界范围内癌症死亡率较高的肿瘤之一。肝切除术(partial hepatectomy)是重要的治疗手段,然而,许多患者因肿瘤分期晚或潜在的慢性肝病和/或肝硬化不能接受肝切除术或肝移植术(liver transplantation)。此类患者,目前可选择肝动脉栓塞化疗(transarterial chemoembolization,TACE)、射频消融(radiofrequency ablation,RFA)、放射治疗、靶向治疗及免疫治疗等方法。肝癌诊断、治疗方式、对肝脏辐射耐受性的生物学理解和放疗技术的进步使得肝癌放射治疗的有效性和安全性都在不断提高,肝癌患者的生存和预后不断改善。Hepatocellular carcinoma(HCC)is one of the leading causes of cancer death worldwide.Liver resection is an important treatment option,but many hepatocellular carcinoma patients cannot undergo partial hepatectomy or liver transplantation due to tumor stage late or chronic liver disease and/or cirrhosis.For patients who can not or refuse to surgery,transarterial chemoembolization,radiofrequency ablation,radiotherapy,targeted therapy and immunotherapy are optional.The progress in the diagnosis and treatment of HCC advances in the biological understanding of liver-radiation tolerances and radiotherapy technology have made the effectiveness and safety of radiotherapy for HCC improved and the survival and prognosis of HCC patients are improving.

关 键 词：肝细胞肝癌 放射治疗 门静脉癌栓 

分 类 号：R733.2[医药卫生—肿瘤]